Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia Arthur Gomes Oliveira Braga; Katia Borgia Barbosa Pagnano; Marina Dal'Bó Pelegrini Campioni; Ana Beatriz Pascoal Lopes; Gislaine Oliveira Duarte; Konradin Metze; Irene Lorand-Metze;

REVERSAL OF ACCELERATED PHASE CML WITH HIGH BLAST COUNT FOLLOWING 5+2 CHEMOTHERAPY AND DASATINIB: A CASE REPORT Bü¿ra Akdo¿an; Ali Turunç; Birol Güvenç;

Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies Tomasz Sacha; Katarzyna Krawczyk;